Peptide Schedule
Leuprolide (Lupron)9 residuesHWSYGLRPGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Leuprolide (Lupron)
Benefits
About Leuprolide (Lupron)
Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH/LHRH). First approved by the FDA in 1985, it is one of the most widely prescribed peptide drugs in the world, marketed under brand names including Lupron, Lupron Depot, and Eligard. Leuprolide is approximately 15-20 times more potent than native GnRH due to a D-leucine substitution at position 6 and an ethylamide group replacing the C-terminal glycine, which confer resistance to enzymatic degradation. The defining pharmacological feature of leuprolide is its biphasic effect on the hypothalamic-pituitary-gonadal (HPG) axis. Initial administration acts as a strong GnRH agonist, stimulating the pituitary to release LH and FSH, which in turn drives a transient increase in sex steroid production — testosterone in males, estrogen and progesterone in females. This "flare" phase lasts approximately 1-2 weeks. With continued administration, sustained receptor stimulation causes downregulation and desensitization of pituitary GnRH receptors through beta-arrestin-mediated internalization. The result is a profound suppression of LH and FSH secretion, leading to castrate levels of testosterone (<50 ng/dL in males) or postmenopausal levels of estradiol in females. This mechanism makes leuprolide effective across a wide range of hormone-dependent conditions. In advanced prostate cancer, it provides androgen deprivation therapy comparable to surgical castration. In endometriosis and uterine fibroids, the induced hypoestrogenic state shrinks lesions and reduces pain. In central precocious puberty, it halts premature sexual development until an appropriate age. Leuprolide is also used as part of transgender hormone therapy and in assisted reproduction protocols. The peptide is primarily degraded by peptidases rather than cytochrome P-450 enzymes, with approximately 46% plasma protein binding. Following subcutaneous injection, the terminal elimination half-life is about 3 hours. Depot formulations use microsphere or polymer matrix technology to sustain drug release over 1-6 months from a single injection, maintaining therapeutic suppression without daily dosing.
Who Should Consider Leuprolide (Lupron)
- Men with advanced or metastatic prostate cancer requiring androgen deprivation therapy
- Women with endometriosis-related pelvic pain unresponsive to first-line treatments
- Women with symptomatic uterine fibroids, particularly as pre-surgical adjunct therapy
- Children with central precocious puberty requiring suppression of premature sexual development
- Transgender individuals using GnRH agonists as part of hormone therapy protocols
- Women undergoing IVF who need to prevent premature LH surges during controlled ovarian stimulation
How Leuprolide (Lupron) Works
Leuprolide binds to GnRH receptors (GnRHR) on gonadotroph cells in the anterior pituitary with substantially greater affinity and duration than endogenous GnRH. The D-Leu6 substitution resists degradation by endopeptidases, and the des-Gly10-ethylamide C-terminal modification enhances receptor binding, making the analog 15-20x more potent than native GnRH. Upon initial binding, leuprolide activates the Gq/11 signaling pathway, triggering phospholipase C-mediated inositol trisphosphate (IP3) production and intracellular calcium release. This stimulates the exocytosis of stored LH and FSH granules — the "flare" effect. Testosterone levels in males can surge approximately 50% above baseline during the first 1-2 weeks, and estrogen similarly rises in females. With continuous exposure from depot formulations, the GnRH receptors undergo sustained activation that triggers beta-arrestin recruitment and receptor internalization via clathrin-coated pits. The internalized receptors are directed toward lysosomal degradation rather than recycling to the cell surface. This progressive loss of surface GnRHR, combined with uncoupling of the Gq signaling cascade, renders gonadotroph cells refractory to further GnRH stimulation. LH and FSH secretion falls to negligible levels within 2-4 weeks. The downstream consequence is suppression of gonadal steroidogenesis. In males, testosterone drops to castrate levels (<50 ng/dL) as Leydig cells lose their LH-mediated stimulation. In females, estradiol falls to postmenopausal levels. This chemical castration is reversible upon drug discontinuation, though recovery of the HPG axis may take weeks to months.
What to Expect
Initial GnRH agonist flare begins. LH and FSH rise sharply. Testosterone or estrogen levels start increasing above baseline.
Peak flare effect. Testosterone may surge ~50% above baseline in males. Temporary symptom worsening possible — tumor flare in prostate cancer, increased pelvic pain in endometriosis. Anti-androgen cover recommended during this window for prostate cancer.
GnRH receptor downregulation takes effect. LH and FSH begin falling. Testosterone/estrogen levels decline progressively toward suppressed ranges.
Full biochemical suppression achieved. Testosterone reaches castrate levels (<50 ng/dL) in the majority of patients. Symptom improvement begins in endometriosis and fibroid patients.
Sustained hormonal suppression maintained by depot formulation. Prostate cancer: PSA decline and disease stabilization. Endometriosis: pain relief and lesion regression. Fibroids: volume reduction of 30-60%. Monitor bone mineral density.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mg | Daily |
| Moderate | 7.5mg | Monthly |
| Aggressive | 22.5mg | Monthly |
Note: Leuprolide is available in multiple formulations with very different dosing schedules. The DAILY subcutaneous injection (Lupron Injection) is 1 mg/day SC. The DEPOT formulations (Lupron Depot, Eligard) are intramuscular or subcutaneous injections given on fixed schedules: 7.5 mg monthly, 22.5 mg every 3 months, 30 mg every 4 months, or 45 mg every 6 months. The "Weekly" frequency selected above is the closest valid option but does NOT reflect actual clinical dosing — depot injections are given monthly to every 6 months depending on formulation. Dosing varies by indication: prostate cancer uses 7.5-45 mg depot, endometriosis and fibroids use 3.75 mg monthly or 11.25 mg every 3 months for up to 6 months, and central precocious puberty uses weight-based dosing starting at 7.5-15 mg monthly. IMPORTANT: The first 1-2 weeks of therapy cause a "flare" — a transient surge in testosterone (males) or estrogen (females) that can temporarily worsen symptoms. In prostate cancer, anti-androgen cover (e.g., bicalutamide) is often co-prescribed for the first 2-4 weeks to block flare effects.
How to Inject Leuprolide (Lupron)
Lupron Depot kits contain lyophilized microspheres and a diluent for reconstitution. Follow the manufacturer instructions for the specific depot size: tap the vial to loosen powder, inject the diluent, and swirl gently (do not shake) until a uniform milky suspension forms. Inject immediately IM (gluteal) or SC (abdomen or thigh for Eligard). Do not store after reconstitution. For the daily SC formulation (Lupron Injection, 5 mg/mL solution): inject 0.2 mL (1 mg) subcutaneously once daily, rotating injection sites. Depot schedule by formulation: 7.5 mg every 1 month, 22.5 mg every 3 months, 30 mg every 4 months, or 45 mg every 6 months. Confirm testosterone suppression with serum levels at 1 month and periodically thereafter. In prostate cancer, prescribe concurrent anti-androgen therapy (e.g., bicalutamide 50 mg/day) for the first 2-4 weeks to mitigate flare. Monitor bone mineral density at baseline and annually during prolonged use. Counsel patients about the expected flare phase and its symptoms.
Cycling Protocol
Cycling depends entirely on indication. Prostate cancer: continuous therapy, often lifelong or until disease progression — no "off" period. Endometriosis: limited to 6 months due to bone density loss; a second 6-month course with hormonal add-back (norethindrone 5 mg/day) may be considered. Uterine fibroids: 3-6 months maximum, typically pre-surgical. Central precocious puberty: continued until appropriate age for puberty onset (typically age 11 for girls, 12 for boys), then discontinued to allow normal pubertal development.
Pharmacokinetics
Source: FDA prescribing information: terminal elimination half-life of approximately 3 hours after IV bolus in healthy male volunteers. Depot formulations sustain therapeutic drug levels for 1-6 months via microsphere/polymer matrix controlled release.
Loading the interactive decay curve.
Side Effects
Common effects stem from the induced hypogonadal state and differ by sex. In males: hot flashes (50-80%), decreased libido, erectile dysfunction, fatigue, gynecomastia, and testicular atrophy. In females: hot flashes, vaginal dryness, headache, mood changes, decreased libido, and breakthrough bleeding during the first weeks. In both sexes, long-term use causes significant bone mineral density loss — studies show 3-6% lumbar spine BMD decrease within 6 months. This loss may not fully recover after discontinuation, and prolonged therapy increases the risk of osteopenia, osteoporosis, and fracture. Other reported effects include injection site reactions, peripheral edema, myalgia, arthralgia, depression, and memory impairment. The initial flare can cause disease-specific worsening: tumor flare and urinary obstruction in prostate cancer, increased pelvic pain in endometriosis, or temporary uterine bleeding. Rare but serious effects include cardiovascular events (increased risk of MI and stroke with long-term ADT), QT prolongation, seizures (rare), and anaphylaxis.
Contraindications
- Pregnancy — Category X. Leuprolide can cause fetal harm, spontaneous abortion, and birth defects. Pregnancy must be excluded before starting therapy and non-hormonal contraception used during treatment.
- Known hypersensitivity to GnRH, GnRH agonist analogs (including leuprolide, goserelin, triptorelin), or any formulation component
- Undiagnosed abnormal vaginal bleeding — must be investigated before initiating therapy
- Breastfeeding — potential for serious adverse reactions in nursing infants
- Severe osteoporosis or high fracture risk without bone-protective co-therapy — leuprolide accelerates bone loss
- History of spinal cord compression or urinary tract obstruction in prostate cancer patients who cannot receive concurrent anti-androgen therapy during the flare phase
Drug Interactions
- Anti-androgens (bicalutamide, flutamide, enzalutamide) — intentionally co-prescribed during flare to block testosterone effects; not a contraindication but a planned combination
- QT-prolonging drugs (amiodarone, sotalol, certain antipsychotics) — additive risk of QT prolongation and arrhythmias with androgen deprivation
- GnRH antagonists (degarelix, cetrorelix, relugolix) — pharmacological antagonism; should not be used concurrently
- Exogenous sex steroids (testosterone, estrogen, progestins) — counteract the intended suppressive effect of leuprolide
- Drugs affecting pituitary gonadotropin secretion (dopamine agonists, high-dose corticosteroids) — may alter the hormonal response to leuprolide
Storage & Stability
Molecular Profile
Related Peptides
References
- Leuprolide acetate: a drug of diverse clinical applicationsPubMed 17970643
- Leuprorelin: a review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disordersPubMed 7533699
- Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month studyPubMed 9464714
- Long-term effects on bone mineral density of 6 months treatment with GnRH analoguesPubMed 16133689
- Leuprolide - StatPearls (NCBI Bookshelf)Review
- Lupron Depot (leuprolide acetate) FDA Prescribing InformationFDA Label